Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5.pdf

下载文档

2
0
约2.7万字
约 6页
2017-04-11 发布于江苏
举报
版权申诉
保障服务

Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5.pdf

1、本文档共6页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5

MOLECULAR MEDICINE REPORTS 11: 2147-2152, 2015 Abstract. Hepatocellular carcinoma (HCC) is one of the most common cancer types, and chemotherapy plays an important role in treatment of HCC. However, long-term treatment with chemotherapeutic drugs such as 5?fluorouracil (5-FU) often results in chemoresistance, and the underlying mechanisms remain unclear. In this study, we showed that the annexin A2 (ANXA2) protein is highly expressed in hepatoma cells compared to healthy cells. Knockdown of the ANXA2 gene inhibited hepatoma cell growth, and the underlying mechanism may involve cell cycle inhibition through down- regulation of β-catenin and cyclin D1. We also investigated the role of ANXA2 in chemotherapeutic treatment with 5-FU. 5-FU inhibited hepatoma cell growth, while ANXA2 overexpression reduced, and knockdown enhanced, the effects of 5-FU on hepatoma cell growth. Furthermore, β-catenin and cyclin D1 were asscociated with the ANXA2-induced resistance. Taken together, our data suggest that the ANXA2 protein is a critical factor in HCC and that its downregulation can enhance chemotherapeutic treatment with 5-FU. ANXA2 may thus constitute a new therapeutic target for HCC. Introduction Hepatocellular carcinoma (HCC) is one of the most common cancer types worldwide and has an extremely poor prog- nosis (1,2). Certain risk factors, such as chronic hepatitis B and C virus infections, exposure to aflatoxin, non?alcoholic fatty liver disease and diabetes, contribute to HCC development. Although the etiology of HCC is well documented, the ability to treat HCC remains limited. Chemotherapy is commonly used in treatment of HCC. 5-Fluorouracil (5-FU) has been used to treat various cancer types, and is considered as a first?line anticancer drug for HCC chemotherapy worldwide. Unfortunately, its use is limited, since long-term treatment with this drug often results in chemoresistance, and the underlying mechanisms remain unclear (3,4). Therefore